Immuneering Corp (IMRX) — SEC Financial Statements & Analysis

Immuneering Corp (IMRX) is a pharmaceutical preparations company, incorporated in DE. Immuneering Corp trades on Nasdaq as: IMRX. Immuneering Corp (IMRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Immuneering Corp carries a market cap of $322.84M, a P/E ratio of -5.64x, a P/B ratio of 1.69x, a P/S ratio of 493989.56x, an enterprise value of $281.51M, and an EV/EBITDA multiple of -4.46x. On profitability, it posts an operating margin of -12328770.77%, a net margin of -11348063.96%, a Return on Equity (ROE) of -52.15%, a Return on Assets (ROA) of -47.31%, and a Return on Invested Capital (ROIC) of -83.52%. Per share, it reports EPS of $-0.89, diluted EPS of $-0.89, free cash flow per share of $-0.88, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -7.81% year-over-year, and EPS growth of -48.72% year-over-year. On the balance sheet, it maintains a current ratio of 19.47x, a quick ratio of 18.47x, working capital of $149.87M, a debt-to-equity ratio of 0.06x, a debt ratio of 0.06, free cash flow of $-56.99M (TTM), and net debt of $-41.32M. Figures sourced from SEC EDGAR.

Market Cap

$322.84M

P/E TTM

-5.64x

EPS TTM

$-0.89

P/B TTM

1.69x

ROE TTM

-52.15%

ROA TTM

-47.31%

Debt To Equity

0.06x

Free Cash Flow TTM

$-56.99M

Net Revenue TTM Growth 1Y

-100.00%

Data as of 2026-06-30 · Source: SEC EDGAR